{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"292"}],"units":"Participants"}],"description":"An adverse event (AE) is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.","groups":[{"description":"Participants received pembrolizumab 200 mg IV every Q3W for up to 35 administrations (up to \\~2 years).","id":"OG000","title":"Pembrolizumab"},{"description":"Participants received capecitabine, eribulin, gemcitabine, or vinorelbine as single agent chemotherapy chosen by the treating physician (Treatment of Physician's Choice, TPC) in accordance with local regulations and guidelines.","id":"OG001","title":"Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All randomized participants who received at least 1 dose of study treatment","reportingStatus":"POSTED","timeFrame":"Up to approximately 60 months","title":"Number of Participants Who Discontinued Study Treatment Due to an Adverse Event","type":"SECONDARY","unitOfMeasure":"Participants"}